Full Press Release Details
NOT FOR PROMOTIONAL USE Key Highlights 3 Proprietary AMPPLIFY drug delivery technology to enhance delivery to target tissues of the eye IP protection for AMPPLIFY technology and products through 2033 AMPPLIFY TM Technology Approved by FDA in August 2018 with U.S. launch in January 2019 FIRST & ONLY post - surgical steroid with class - leading combination of powerful efficacy, safety profile comparable to vehicle, and BID dosing In 2019, generated over 127k TRxs and 8.6% branded NRx market share, and achieved 75% Commercial coverage and 23% Part D coverage INVELTYS EYSUVIS TM (KPI - 121 0.25%) for Dry Eye Disease Potential preferred Rx therapy for Dry Eye flares STRIDE 3 Phase 3 trial expected to be fully enrolled this week and remains on track for topline data in 1Q2020 Corporate Highlights Well capitalized with cash of $85.4 million as of December 31, 2019 Existing cash resources, together with projected INVELTYS revenue, expected to fund operations at least through 1Q2021